12 results about "Mouse tissue" patented technology

The invention discloses a periodontitis marker and application thereof. Belongs to the technical field of biomedical detection. Experiments prove that the expression of the hsacirc0005737 in patient tissues, periodontal ligament stem cells in an inflammation microenvironment and periodontitis model mouse tissues is remarkably up-regulated, and the expression level of the hsacirc0005737 is positively correlated with the severity and activity of periodontitis. Therefore, detection of the expression level can be used for diagnosis, activity evaluation, curative effect monitoring and prognosis of periodontitis. In addition, the osteogenic differentiation capacity and inflammatory response of the periodontal ligament stem cells can be influenced by regulating the expression of the hsacirc0005737, so that the hsacirc0005737 can be used as a potential target for treating periodontitis. The invention further provides a primer sequence, a detection reagent combination and a kit for detecting the hsacirc0005737, and a new solution is provided for noninvasive, early-stage and high-specificity diagnosis and targeted therapy of periodontitis.

The invention discloses a 15-antibody combination for accurately detecting a mouse tissue immune cell subset and application of the 15-antibody combination. Aiming at the problems of large fluctuation and instability of detection results caused by adjustment of voltage and fluorescence compensation during detection by a flow cytometer and different processing modes during result analysis, the antibody combination disclosed by the invention takes monoclonal antibodies CD45, CD3, CD4, CD8, CD19, B220, Ly-6C, Ly-6G, MHC-II, CD11c, CD49b, CD62L, CD44 +, PD-1 and PD-L1 as effective components, and a stable and standard detection method for mouse tissue immune cell subsets is established. The method can analyze the proportion, number and distribution of various immune cells (T cells, B cells, NK cells, dendritic cells, mononuclear cells and granulocytes) in spleen, lung, liver, brain or kidney tissues of mice, can reflect the immune state of the mice and evaluate the immunosuppression state, and can be applied to the fields of disease models, drug evaluation, vaccine development and the like.

This invention discloses an adjustable stimulation application device for mouse pain experiments, relating to the field of veterinary surgical instrument technology. It includes an operating base and a control device fixedly mounted on the operating base. A surgical fixation table for mounting and fixing a mouse device is fixedly mounted on the operating base. A fixing block is fixedly mounted on the operating base, with a longitudinal groove inside the fixing block. A horizontal adjustment mechanism is provided on the fixing block, and an insertion mechanism is provided on the horizontal adjustment mechanism. The insertion mechanism is used to insert into mouse tissue to apply pain stimulation to the mouse. A longitudinal adjustment part is provided on the fixing block for adjusting the position of the horizontal adjustment mechanism. This device can precisely control the application position and insertion depth of the pain stimulation, meeting the control requirements of different stimulation intensities in pain experiments, effectively improving the consistency and accuracy of stimulation application in mouse pain experiments, and reducing experimental errors caused by manual operation.

The application discloses a method for relieving obesity cardiomyopathy lipid toxicity by Chemerin and belongs to the technical field of pharmacological research. Mice are selected to establish an obesity mouse model, and are equally divided into a control group, a high-fat diet group, an AAV CMKLR1 virus group, and a high-fat + AAV CMKLR1 virus group. In succession, mouse heart ultrasound, TSE system detection, glucose tolerance test, and insulin tolerance test are carried out, and mouse blood glucose is measured at intervals. Then, tissue protein is extracted for protein immunoblotting, and tissue RNA is extracted for reverse transcription, and then qPCR is used to detect the expression of related genes. After paraffin embedding and slicing of mouse tissues, HE, WGA, immunofluorescence and other pathological staining are carried out. MTBE method is used for lipid extraction and detection of lipid content. ELISA method is used to measure serum Chemerin, and Acyl-RAC method is used to detect protein palmitoylation. Finally, the experimental results are analyzed to draw a conclusion. The present application proves by clinical data and mouse models that Chemerin compensatorily increases in the process of obesity, and Chemerin can relieve cardiac lipid toxicity caused by obesity and protect cardiac function.

The application provides a rat TEX264 recombinant protein, a recombinant vector, a polyclonal antibody and application, and relates to the technical field of biological engineering.The amino acid sequence of the rat TEX264 recombinant protein is shown as SEQ ID NO.2.The application provides a preparation method of an anti-rat TEX264 polyclonal antibody, and a polyclonal antibody against rat TEX264 is prepared; the antibody can specifically recognize endogenous TEX264 protein of a rat, and is used for experiments such as ELISA, Western Blot, immunofluorescence analysis and the like.The application provides a material basis for studying the function of TEX264.The antibody of the application can detect TEX264 protein of human and mouse tissues in addition to recognizing and detecting rat TEX264, compared with a related antibody on the market which can only detect TEX264 protein of mouse and / or human tissue samples; the antibody can simultaneously detect TEX264 protein of rat, mouse and human tissue samples, and is suitable for various different detection methods such as Western Blot, immunohistochemistry and immunofluorescence, and has advantages in economic benefits.

The invention discloses a method for drawing a mouse full-coverage protein interaction network through bacterial single cell transcriptome sequencing. The method comprises the following steps: firstly, extracting mRNA (messenger ribonucleic acid) of pan-tissue of a mouse, and then obtaining a cDNA (complementary deoxyribonucleic acid) library by adopting a modified random primer or an oligo-dT primer; carrying out homogenization treatment on the mouse protein library; the method comprises the following steps: transforming plasmids of a BACTH bacteria double-hybrid system to obtain transformed plasmids; carrying out homologous recombination on the transformed plasmids of the sample library and the double hybrid system, and introducing into DHM1 escherichia coli for screening to obtain positive PPI clone with a mutual composition library; and carrying out single-cell transcriptome sequencing on the screened clones based on random primers to construct the mouse protein interaction network. The method is used for carrying out high-throughput screening on mice after thousands of positive PPI combinatorial clones are obtained by'library-to-library 'bacteria or yeast double hybrids, and identifying the same Barcode cDNA combinatorial pairs to realize PPI network identification in different species, among species and in hybridization technology system extensive scenes.

The invention discloses an application of epigallocatechin gallate (EGCG) in preparation of a medicine for preventing and treating high-temperature heatstroke, and particularly discloses an application of the EGCG in preparation of the medicine for preventing and treating the high-temperature heatstroke. The EGCG disclosed by the invention can be used for intervening the pathophysiological process of mouse heatstroke by inhibiting cell death induced by high temperature. In a mouse heatstroke model, EGCG pretreatment can effectively inhibit cell death induced by high temperature, meanwhile, mouse tissue damage caused by high temperature can be remarkably improved, and the survival rate of mice is increased. Therefore, when the EGCG is applied to prevention and treatment of heatstroke, tissue damage caused by high temperature can be effectively relieved, and the case fatality rate can be reduced. Besides, EGCG serving as a natural compound has high safety and good tolerance, and compared with a traditional medicine, the EGCG is smaller in side effect and wider in application range.

The invention provides a portable mouse tissue experimental device, and particularly relates to the technical field of experimental equipment.The portable mouse tissue experimental device comprises a separating device, the separating device comprises a first annular component and a suture line, a plurality of circular holes are formed in the side wall of the first annular component, and the suture line is arranged in the circular holes; according to the invention, the mouse is separated and fixed by using the suture line, and the anesthetized mouse is matched with the suture line of different circular holes through different mice, so that the skin or muscle of all places of the mouse can be separated and fixed; and a target tissue area can be better, rapidly, completely and safely exposed.

The application relates to a method for establishing a systemic amyloidosis model and application, a systemic amyloidosis model is established by injecting amyloidosis lysozyme into the tail vein of a mouse to induce amyloidosis of the mouse tissue, the systemic amyloidosis model obtained can simulate the pathological state of systemic amyloidosis in the body, is used for activity screening of amyloidosis prevention and treatment drugs, and has a good application prospect in the treatment and prevention of amyloidosis.

The invention discloses application of all-trans retinoic acid in preparation of a medicine for preventing and / or treating novel bunyavirus infectious diseases, and belongs to the field of medicines. Experiments prove that the all-trans retinoic acid can reduce the mouse death proportion caused by novel bunyavirus infection and reduce mouse tissue damage. In addition, in-vivo and in-vitro experiments find that all-trans retinoic acid reduces expression of inflammatory factors through PPAR gamma protein. Therefore, the all-trans retinoic acid can be used for preparing the medicine for resisting the novel bunyavirus and / or the medicine for preventing or treating the novel bunyavirus infectious diseases and / or the medicine for inhibiting the inflammation of the novel bunyavirus infectious diseases.

The invention discloses an antibody for specifically recognizing ATAD3A phosphorylation modification and application of the antibody. According to the present invention, the research results show that the ATAD3A Ser321 site in senescent cells is the key phosphorylation site, and the antibody specifically recognizing ATAD3A Ser321 phosphorylation is obtained through immunization aiming at the site; the antibody has relatively strong specificity, and can be used for successfully detecting the expression of phosphorylated ATAD3A in senescent cells and the level of phosphorylated ATAD3A in tissues and organs of mice. According to the antibody, the market vacancy that a specific detection antibody for ATAD3A phosphorylation is lacked at present is filled, the antibody can be applied to Western blot and immunohistochemical detection of ATAD3A phosphorylation level in scientific research, and support is provided for mitochondrial related action mechanisms and anti-aging treatment research in the aging process.

The invention relates to the technical field of vaccine preparation, in particular to application of a PmCQ6007170 gene in preparation of a bovine-derived A-type pasteurella multocida vaccine. According to the invention, the PmCQ6007170 strain is constructed by knocking out the PmCQ6007170 gene, the growth speed and the biofilm content of the PmCQ6007170 are remarkably increased, and the capsule content and the serum sensitivity are remarkably reduced; in addition, the colonization amount of the PmCQ6007170 in mouse tissues (lung, liver and spleen) and lung tissue inflammatory injury are remarkably reduced, and the toxicity is remarkably reduced (PmCQ6007170: LD50 = 2.29 * 10 < 11 > CFU); the attenuated vaccine prepared from the PmCQ6007170 has 100% of protective efficacy, 70% of protective efficacy and 50% of protective efficacy on mice infected with PmA (PmCQ2: virulent strain), mice infected with PmB (PmB) and mice infected with PmF (PmF) respectively; the invention provides an important theoretical basis for developing a PmA attenuated vaccine with a cross immune protection effect.